

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version 2.17      Revision Date: 30.09.2023      SDS Number: 441602-00019      Date of last issue: 04.04.2023  
Date of first issue: 06.01.2016

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Orbifloxacin / Posaconazole / Mometasone Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Veterinary product

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Kilsheelan  
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

1-908-423-6000

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2      H319: Causes serious eye irritation.  
Long-term (chronic) aquatic hazard, Category 2      H411: Toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

Signal word : Warning

Hazard statements : H319 Causes serious eye irritation.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**

P264 Wash skin thoroughly after handling.  
P273 Avoid release to the environment.  
P280 Wear eye protection/ face protection.

**Response:**

P337 + P313 If eye irritation persists: Get medical advice/  
attention.  
P391 Collect spillage.

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Orbifloxacin	113617-63-3	Repr. 2; H361d	>= 1 - < 3
Posaconazole	171228-49-2	Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 1; H372 (Adrenal gland, Bone marrow, Kidney, Liv- er, Nervous system, Reproductive organs) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 <hr/> M-Factor (Acute	>= 0.1 - < 0.25

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version 2.17      Revision Date: 30.09.2023      SDS Number: 441602-00019      Date of last issue: 04.04.2023  
Date of first issue: 06.01.2016

		aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1	
Mometasone	83919-23-7	Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410  M-Factor (Chronic aquatic toxicity): 100	>= 0.1 - < 0.25

For explanation of abbreviations see section 16.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

---

Risks : Causes serious eye irritation.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages  
cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate contain-  
ment to keep material from spreading. If dyked material can  
be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absor-  
bent.  
Local or national regulations may apply to releases and dis-  
posal of this material, as well as those materials and items  
employed in the cleanup of releases. You will need to deter-  
mine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding  
certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE  
CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust  
ventilation.

Advice on safe handling : Do not get on skin or clothing.  
Do not breathe vapours or spray mist.  
Do not swallow.  
Do not get in eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety  
practice, based on the results of the workplace exposure as-  
sessment  
Keep container tightly closed.  
Take care to prevent spills, waste and minimize release to the  
environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye  
flushing systems and safety showers close to the working  
place. When using do not eat, drink or smoke. Wash contami-  
nated clothing before re-use.  
The effective operation of a facility should include review of  
engineering controls, proper personal protective equipment,  
appropriate degowning and decontamination procedures,  
industrial hygiene monitoring, medical surveillance and the  
use of administrative controls.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version 2.17      Revision Date: 30.09.2023      SDS Number: 441602-00019      Date of last issue: 04.04.2023  
Date of first issue: 06.01.2016

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Keep tightly closed.  
Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
White mineral oil (petroleum)	8042-47-5	OELV - 8 hrs (TWA) (inhalable fraction)	5 mg/m <sup>3</sup>	IE OEL
Orbifloxacin	113617-63-3	TWA	0.2 mg/m <sup>3</sup> (OEB 2)	Internal
Posaconazole	171228-49-2	TWA	300 µg/m <sup>3</sup> (OEB 2)	Internal
Mometasone	83919-23-7	TWA	1 µg/m <sup>3</sup> (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm <sup>2</sup>	Internal

### 8.2 Exposure controls

#### Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

#### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

---

Hand protection		potential for direct contact to the face with dusts, mists, or aerosols.
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 14387
Filter type	:	Combined particulates and organic vapour type (A-P)

---

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

Physical state	:	suspension
Colour	:	white to off-white
Odour	:	odourless
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Auto-ignition temperature	:	No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

---

Decomposition temperature : No data available

pH : No data available

Viscosity  
Viscosity, kinematic : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-  
octanol/water : Not applicable

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics  
Particle size : Not applicable

### 9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : None known.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Remarks: No significant adverse effects were reported  
No mortality observed at this dose.

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Remarks: No significant adverse effects were reported

#### Components:

##### **Orbifloxacin:**

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg  
Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2,000 mg/kg  
Remarks: No mortality observed at this dose.

LD50 (Dog): > 600 mg/kg  
Symptoms: Vomiting  
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 200 mg/kg  
Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg  
Application Route: Intramuscular

LD50 (Rat): 233 mg/kg  
Application Route: Intravenous

LD50 (Mouse): 250 mg/kg

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

---

Application Route: Intravenous

### Posaconazole:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
LD50 (Mouse): > 3,000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

### Mometasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg  
Application Route: Subcutaneous  
Symptoms: Breathing difficulties

### Skin corrosion/irritation

Not classified based on available information.

### Product:

Species : Rabbit  
Result : Mild skin irritation

### Components:

#### Orbifloxacin:

Species : Rabbit  
Method : Draize Test  
Result : No skin irritation

#### Posaconazole:

Species : Rabbit  
Result : No skin irritation

#### Mometasone:

Species : Rabbit  
Result : No skin irritation

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

---

### Serious eye damage/eye irritation

Causes serious eye irritation.

#### Product:

Species : Rabbit  
Result : Mild eye irritation

#### Components:

##### **Orbifloxacin:**

Species : Rabbit  
Method : Draize Test  
Result : Mild eye irritation

##### **Posaconazole:**

Species : Rabbit  
Result : Mild eye irritation

##### **Mometasone:**

Species : Rabbit  
Result : No eye irritation

### Respiratory or skin sensitisation

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

#### Product:

Test Type : Magnusson-Kligman-Test  
Exposure routes : Dermal  
Result : Not a skin sensitizer.

#### Components:

##### **Orbifloxacin:**

Test Type : Maximisation Test  
Exposure routes : Dermal  
Species : Guinea pig  
Result : Not a skin sensitizer.

##### **Posaconazole:**

Test Type : Magnusson-Kligman-Test  
Exposure routes : Skin contact  
Species : Guinea pig

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

Result : negative

### Mometasone:

Test Type : Maximisation Test  
Exposure routes : Dermal  
Species : Guinea pig  
Assessment : Does not cause skin sensitisation.  
Result : negative  
Remarks : The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Orbifloxacin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: equivocal

Test Type: Mouse Lymphoma  
Result: positive

Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Intraperitoneal injection  
Result: negative

Test Type: unscheduled DNA synthesis assay  
Species: Rat  
Cell type: Liver cells  
Application Route: Oral  
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

#### Posaconazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

---

Species: Mouse  
Cell type: Bone marrow  
Application Route: Intravenous  
Result: negative

### **Mometasone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: positive

Test Type: Mouse Lymphoma  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Test Type: Chromosomal aberration  
Species: Rat  
Cell type: Bone marrow  
Result: negative

Test Type: unscheduled DNA synthesis assay  
Species: Rat  
Cell type: Liver cells  
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### **Carcinogenicity**

Not classified based on available information.

### **Components:**

#### **Orbifloxacin:**

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 200 mg/kg body weight  
Result : negative

Species : Mouse

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

---

Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 200 mg/kg body weight  
Result : negative

### Posaconazole:

Species : Rat  
Application Route : oral (feed)  
Exposure time : 2 Years  
Result : positive  
Remarks : The mechanism or mode of action is not relevant in humans.

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
Result : positive  
Remarks : The mechanism or mode of action is not relevant in humans.

### Mometasone:

Species : Rat  
Application Route : Inhalation  
Exposure time : 2 Years  
Dose : 0.067 mg/kg body weight  
Result : negative

Species : Mouse  
Application Route : Inhalation  
Exposure time : 19 Months  
Dose : 0.160 mg/kg body weight  
Result : negative

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Orbifloxacin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
General Toxicity - Parent: NOAEL: 50 mg/kg body weight  
Early Embryonic Development: NOAEL: 50 mg/kg body weight  
Result: No adverse effects

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight  
Result: No teratogenic effects, Embryotoxic effects and ad-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

verse effects on the offspring were detected only at high maternally toxic doses

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 20 mg/kg body weight  
Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight  
Result: No effects on early embryonic development, Embryo-toxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain

Test Type: Development  
Species: Dog  
Application Route: Oral  
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight  
Result: Effects on postnatal development, Skeletal malformations

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### Posaconazole:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male  
General Toxicity - Parent: NOAEL: 180 mg/kg body weight  
Symptoms: No effects on mating performance  
Result: negative

Test Type: Fertility/early embryonic development  
Species: Rat, female  
General Toxicity - Parent: NOAEL: 45 mg/kg body weight  
Symptoms: No effects on mating performance  
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat, female  
Application Route: Oral  
Developmental Toxicity: LOAEL: 29 mg/kg body weight  
Result: Fetotoxicity, Malformations were observed.

Test Type: Embryo-foetal development  
Species: Rabbit, female  
Developmental Toxicity: LOAEL: 40 mg/kg body weight  
Result: Fetotoxicity

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

### Mometasone:

- Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Subcutaneous  
Fertility: NOAEL: 0.015 mg/kg body weight  
Symptoms: Reduced embryonic survival, Reduced foetal weight  
Result: No effects on fertility, Effect on reproduction capacity
- Effects on foetal development : Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Subcutaneous  
Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight  
Result: Embryotoxic effects., Teratogenicity and developmental toxicity
- Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Dermal  
Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight  
Result: Embryo-foetal toxicity
- Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Dermal  
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight  
Result: Embryo-foetal toxicity, Malformations were observed.
- Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Subcutaneous  
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight  
Result: Effects on newborn
- Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight  
Result: Embryo-foetal toxicity, Malformations were observed.
- Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

### STOT - single exposure

Not classified based on available information.

### Components:

#### Mometasone:

- Remarks : Based on available data, the classification criteria are not met.



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version 2.17      Revision Date: 30.09.2023      SDS Number: 441602-00019      Date of last issue: 04.04.2023  
Date of first issue: 06.01.2016

---

### STOT - repeated exposure

Not classified based on available information.

### Components:

#### **Posaconazole:**

Exposure routes : Ingestion  
Target Organs : Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

#### **Mometasone:**

Exposure routes : inhalation (dust/mist/fume)  
Target Organs : Immune system, Liver, Kidney, Skin  
Assessment : May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### **Orbifloxacin:**

Species : Rat  
NOAEL : 20 mg/kg  
LOAEL : 80 mg/kg  
Application Route : Oral  
Exposure time : 3 Months  
Target Organs : Testis, Liver, Kidney, spleen

Species : Mouse  
NOAEL : 80 mg/kg  
LOAEL : 250 mg/kg  
Application Route : Oral  
Exposure time : 3 Months

Species : Juvenile dog  
NOAEL : 50 mg/kg  
LOAEL : 250 mg/kg  
Application Route : Oral  
Exposure time : 14 Days  
Target Organs : Heart, Bone  
Symptoms : Gastrointestinal disturbance  
Remarks : mortality observed

Species : Juvenile dog  
NOAEL : 2 mg/kg  
LOAEL : 3 mg/kg  
Application Route : Oral

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version 2.17      Revision Date: 30.09.2023      SDS Number: 441602-00019      Date of last issue: 04.04.2023  
Date of first issue: 06.01.2016

---

Exposure time : 90 Days  
Target Organs : Bone  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 37.5 mg/kg  
Application Route : Oral  
Exposure time : 30 Days

Species : Cat  
NOAEL : 7.5 mg/kg  
LOAEL : 22.5 mg/kg  
Application Route : Oral  
Exposure time : 1 Months  
Symptoms : Gastrointestinal disturbance

### **Posaconazole:**

Species : Rat, female  
LOAEL : 5 mg/kg  
Application Route : Oral  
Exposure time : 6 Months  
Target Organs : Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary

Species : Dog  
LOAEL : 3 mg/kg  
Application Route : Oral  
Exposure time : 392 Days  
Target Organs : Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal cord, lymphoid tissue

Species : Monkey  
LOAEL : 15 mg/kg  
Application Route : Oral  
Exposure time : 1 Months  
Target Organs : Bone marrow, Adrenal gland, Lymph nodes, Blood

Species : Dog  
LOAEL : 3 mg/kg  
Application Route : Oral  
Exposure time : 56 Weeks  
Target Organs : Adrenal gland, Bone marrow, Kidney, Nervous system, spleen, thymus gland, Testis, lymphoid tissue

Species : Monkey  
LOAEL : 180 mg/kg  
Application Route : Oral  
Exposure time : 12 Months  
Target Organs : Blood, Gastrointestinal tract, spleen

Species : Monkey  
LOAEL : 8 mg/kg

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

Application Route : Intravenous  
Exposure time : 1 Months  
Target Organs : Cardio-vascular system, Lungs, Adrenal gland, Blood

### **Mometasone:**

Species : Rat  
NOAEL : 0.005 mg/kg  
LOAEL : 0.3 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog  
LOAEL : 0.5 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat  
NOAEL : 0.00013 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 90 d  
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,  
Kidney, Liver, thymus gland

Species : Dog  
NOAEL : 0.0005 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 90 d  
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,  
Kidney, thymus gland, Liver

### **Aspiration toxicity**

Not classified based on available information.

### **Components:**

#### **Mometasone:**

Not applicable

## 11.2 Information on other hazards

### **Endocrine disrupting properties**

#### **Product:**

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

### Experience with human exposure

#### Components:

##### **Orbifloxacin:**

Ingestion : Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash  
Remarks: May cause photosensitisation.

##### **Posaconazole:**

Ingestion : Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhoea, hypertension, neutropenia, electrolyte imbalance

##### **Mometasone:**

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion  
Skin contact : Symptoms: Dermatitis, Itching

#### **Further information**

#### Components:

##### **Mometasone:**

Remarks : Dermal absorption possible

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

##### **Posaconazole:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.276 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

Exposure time: 72 h  
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 1

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 0.206 mg/l  
Exposure time: 33 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.244 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211  
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 1

### **Mometasone:**

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l  
Exposure time: 96 h  
Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l  
Exposure time: 7 d  
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 5 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l  
Exposure time: 96 h  
Method: US-EPA OPPTS 850.1035  
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 1,000 mg/l  
Exposure time: 3 h

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

---

Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility

NOEC : 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC: 0.00014 mg/l  
Exposure time: 32 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.34 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211  
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 100

### 12.2 Persistence and degradability

#### Components:

##### **Posaconazole:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 28 h  
Method: OECD Test Guideline 314

Stability in water : Degradation half life (DT50): > 30 d  
Method: OECD Test Guideline 111

##### **Mometasone:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)  
Method: OECD Test Guideline 111

### 12.3 Bioaccumulative potential

#### Components:

##### **Posaconazole:**

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

---

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 20  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.15

### **Mometasone:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 107.1  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

### 12.4 Mobility in soil

#### **Components:**

#### **Posaconazole:**

Distribution among environmental compartments : log Koc: 5.52

#### **Mometasone:**

Distribution among environmental compartments : log Koc: 4.02

### 12.5 Results of PBT and vPvB assessment

#### **Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### **Product:**

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

Contaminated packaging : According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.  
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.  
Do not dispose of waste into sewer.  
Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

### SECTION 14: Transport information

#### 14.1 UN number or ID number

ADN	:	UN 3082
ADR	:	UN 3082
RID	:	UN 3082
IMDG	:	UN 3082
IATA	:	UN 3082

#### 14.2 UN proper shipping name

ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Posaconazole)
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Posaconazole)
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Posaconazole)
IMDG	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Mometasone, Posaconazole)
IATA	:	Environmentally hazardous substance, liquid, n.o.s. (Mometasone, Posaconazole)

#### 14.3 Transport hazard class(es)

	Class	Subsidiary risks
ADN	:	9
ADR	:	9
RID	:	9
IMDG	:	9
IATA	:	9

#### 14.4 Packing group



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

---

### ADN

Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9

### ADR

Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9  
Tunnel restriction code : (-)

### RID

Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9

### IMDG

Packing group : III  
Labels : 9  
EmS Code : F-A, S-F

### IATA (Cargo)

Packing instruction (cargo aircraft) : 964  
Packing instruction (LQ) : Y964  
Packing group : III  
Labels : Miscellaneous

### IATA (Passenger)

Packing instruction (passenger aircraft) : 964  
Packing instruction (LQ) : Y964  
Packing group : III  
Labels : Miscellaneous

## 14.5 Environmental hazards

### ADN

Environmentally hazardous : yes

### ADR

Environmentally hazardous : yes

### RID

Environmentally hazardous : yes

### IMDG

Marine pollutant : yes

### IATA (Passenger)

Environmentally hazardous : yes

### IATA (Cargo)

Environmentally hazardous : yes

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:  
Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

E2	ENVIRONMENTAL HAZARDS	Quantity 1 200 t	Quantity 2 500 t
----	-----------------------	---------------------	---------------------

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

#### Full text of H-Statements

H319 : Causes serious eye irritation.  
H360Df : May damage the unborn child. Suspected of damaging fertility.  
H361d : Suspected of damaging the unborn child.  
H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.  
H373 : May cause damage to organs through prolonged or repeated exposure if inhaled.  
H400 : Very toxic to aquatic life.  
H410 : Very toxic to aquatic life with long lasting effects.

#### Full text of other abbreviations

Aquatic Acute : Short-term (acute) aquatic hazard  
Aquatic Chronic : Long-term (chronic) aquatic hazard  
Eye Irrit. : Eye irritation  
Repr. : Reproductive toxicity  
STOT RE : Specific target organ toxicity - repeated exposure  
IE OEL : List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2  
IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - Interna-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.17	30.09.2023	441602-00019	Date of first issue: 06.01.2016

tional Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECl - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Eye Irrit. 2	H319
Aquatic Chronic 2	H411

### Classification procedure:

Based on product data or assessment
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN